For the Inventor, By the Inventor

Enter inventor name

London, United Kingdom

Richard Marais

USPTO Granted Patents = 26 (Patent Applications = 2)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 8

Forward Citations = 168(Granted Patents)

Location History:

Greater London, GB (2014)
London, GB (1998 - 2017)
Manchester, GB (2017 - 2024)

Company Filing History:

Cancer Research Technology Limited

Institute of Cancer Research: Royal Cancer Hospital (the)

The Institute of Cancer Research: Royal Cancer Hospital

Cancer Research Campaign Technology Limited

The Wellcome Trust Limited

6. 2 out of 123

Astex Therapeutics Limited

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

Loading Chart...

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060360 - Lysyl oxidase inhibitors (2024-08-13),

2. 11608330 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2023-03-21),

3. 11325915 - Lysyl oxidase inhibitors (2022-05-10),

4. 10995088 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2021-05-04),

5. 10807974 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2020-10-20),

6. 10167282 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2019-01-01),

7. 9820976 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2017-11-21),

8. 9725447 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2017-08-08),

9. 9540372 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use (2017-01-10),

10. 9439893 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2016-09-13),

11. 9155737 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2015-10-13),

12. 9120789 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2015-09-01),

13. 8912191 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2014-12-16),

14. 8815896 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2014-08-26),

15. 8580497 - Methods for detection of the oncogenic T1796A B-Raf mutation (2013-11-12),

Title: Richard Marais - Innovator in Cancer Treatment

Introduction

Richard Marais, a prominent inventor based in London, GB, has made significant contributions to the field of cancer research through his innovative inventions. With an impressive portfolio of 26 patents, his work focuses on developing novel treatments targeting lysyl oxidase enzymes.

Latest Patents

Among his latest patents, Richard's inventions include compounds serving as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family inhibitors. These compounds show promise in treating conditions mediated by LOX and LOXL, particularly in various forms of cancer. One notable invention includes a LOX inhibitor aimed at cancers associated with EGFR, along with methods for identifying biomarkers that predict patient responsiveness to these inhibitors. Additionally, he has developed methylamine derivatives that also function as lysyl oxidase inhibitors for cancer treatment, further expanding the therapeutic options available in oncology.

Career Highlights

Throughout his career, Richard has worked with esteemed organizations such as Cancer Research Technology Limited and the Institute of Cancer Research: Royal Cancer Hospital. His work in these institutions has facilitated advancements in cancer therapies and has significantly enhanced research efforts in understanding and combating the disease.

Collaborations

Richard has collaborated with notable professionals in the field, including Caroline Joy Springer and Dan Niculescu-Duvaz. These partnerships have fostered an environment of innovation and have contributed to the successful development of his patents and research projects.

Conclusion

Richard Marais stands out as a leading inventor in the realm of cancer research, driven by his commitment to developing effective treatments. With his extensive patent portfolio and collaborative efforts, he continues to impact the healthcare industry and improve therapeutic options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…